These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Correctors and Potentiators Rescue Function of the Truncated W1282X-Cystic Fibrosis Transmembrane Regulator (CFTR) Translation Product. Haggie PM; Phuan PW; Tan JA; Xu H; Avramescu RG; Perdomo D; Zlock L; Nielson DW; Finkbeiner WE; Lukacs GL; Verkman AS J Biol Chem; 2017 Jan; 292(3):771-785. PubMed ID: 27895116 [TBL] [Abstract][Full Text] [Related]
8. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment. Pettit RS Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718 [TBL] [Abstract][Full Text] [Related]
9. Cystic fibrosis transmembrane conductance regulator (CFTR) potentiators protect G551D but not ΔF508 CFTR from thermal instability. Liu X; Dawson DC Biochemistry; 2014 Sep; 53(35):5613-8. PubMed ID: 25148434 [TBL] [Abstract][Full Text] [Related]
10. Cystic fibrosis transmembrane regulator correctors and potentiators. Rowe SM; Verkman AS Cold Spring Harb Perspect Med; 2013 Jul; 3(7):. PubMed ID: 23818513 [TBL] [Abstract][Full Text] [Related]
11. Corrector combination therapies for F508del-CFTR. Hanrahan JW; Matthes E; Carlile G; Thomas DY Curr Opin Pharmacol; 2017 Jun; 34():105-111. PubMed ID: 29080476 [TBL] [Abstract][Full Text] [Related]
12. Fluorescence assay for simultaneous quantification of CFTR ion-channel function and plasma membrane proximity. Prins S; Langron E; Hastings C; Hill EJ; Stefan AC; Griffin LD; Vergani P J Biol Chem; 2020 Dec; 295(49):16529-16544. PubMed ID: 32934006 [TBL] [Abstract][Full Text] [Related]
13. Ivacaftor for the treatment of cystic fibrosis in children under six years of age. Aoyama BC; Mogayzel PJ Expert Rev Respir Med; 2020 Jun; 14(6):547-557. PubMed ID: 32154747 [No Abstract] [Full Text] [Related]
14. Modulators of CFTR. Updates on clinical development and future directions. Bardin E; Pastor A; Semeraro M; Golec A; Hayes K; Chevalier B; Berhal F; Prestat G; Hinzpeter A; Gravier-Pelletier C; Pranke I; Sermet-Gaudelus I Eur J Med Chem; 2021 Mar; 213():113195. PubMed ID: 33524685 [TBL] [Abstract][Full Text] [Related]
15. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis. Skilton M; Krishan A; Patel S; Sinha IP; Southern KW Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009841. PubMed ID: 30616300 [TBL] [Abstract][Full Text] [Related]
16. Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy. Connett GJ Drug Des Devel Ther; 2019; 13():2405-2412. PubMed ID: 31409974 [TBL] [Abstract][Full Text] [Related]
17. Entering the era of highly effective modulator therapies. Dave K; Dobra R; Scott S; Saunders C; Matthews J; Simmonds NJ; Davies JC Pediatr Pulmonol; 2021 Feb; 56 Suppl 1():S79-S89. PubMed ID: 33434412 [TBL] [Abstract][Full Text] [Related]
18. GM1 as Adjuvant of Innovative Therapies for Cystic Fibrosis Disease. Mancini G; Loberto N; Olioso D; Dechecchi MC; Cabrini G; Mauri L; Bassi R; Schiumarini D; Chiricozzi E; Lippi G; Pesce E; Sonnino S; Pedemonte N; Tamanini A; Aureli M Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32599772 [TBL] [Abstract][Full Text] [Related]
19. Cystic fibrosis drug ivacaftor stimulates CFTR channels at picomolar concentrations. Csanády L; Töröcsik B Elife; 2019 Jun; 8():. PubMed ID: 31205003 [TBL] [Abstract][Full Text] [Related]